U.S. NeuroSurgical Holdings Valuation

Is USNU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of USNU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate USNU's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate USNU's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for USNU?

Key metric: As USNU is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for USNU. This is calculated by dividing USNU's market cap by their current book value.
What is USNU's PB Ratio?
PB Ratio	4.3x
Book	US$3.66m
Market Cap	US$13.60m

USNU key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does USNU's PB Ratio compare to its peers?

The above table shows the PB ratio for USNU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	2.9x
TOI Oncology Institute	0.8x	n/a	US$13.0m
SSY SunLink Health Systems	0.3x	n/a	US$5.3m
JYNT Joint	8.4x	138.3%	US$175.8m
IVP Inspire Veterinary Partners	2x	n/a	US$5.8m
USNU U.S. NeuroSurgical Holdings	4.3x	n/a	US$13.6m

Price-To-Book vs Peers: USNU is expensive based on its Price-To-Book Ratio (4.3x) compared to the peer average (2.9x).

Price to Book Ratio vs Industry

How does USNU's PB Ratio compare vs other companies in the US Healthcare Industry?

6 Companies	Price / Book	Estimated Growth	Market Cap
ALR AlerisLife	0.3x	63.8%	US$44.14m
LIFW MSP Recovery	0.01x	n/a	US$11.46m
NVOS Novo Integrated Sciences	0.08x	n/a	US$838.40k
BIMI BIMI Holdings	0.01x	n/a	US$104.71k

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: USNU is expensive based on its Price-To-Book Ratio (4.3x) compared to the US Healthcare industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is USNU's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

USNU PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	4.3x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate USNU's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Elevance Health

US$93.2b

Operates as a health benefits company in the United States.

ELV

US$402.75

1.3%

-13.5%

Centene

US$30.3b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$59.93

1.4%

-15.0%

Sensus Healthcare

US$141.1m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

SRTS

US$8.60

-3.8%

252.5%